WindMIL Therapeutics→∏☆ and University of California, Irvine Announce Cε♠ollaboration to Collect Bδ✘δ>one Marrow from Pati↔± ents with GliomasWEDNESDAY, OCTOBER 16, 2019Wi©≈≤εndMIL Therapeutics and the Univ £δersity of California, Irvine (UCI♣'→) today announced that the first patients have beδ↑ →en identified in an investigator-sponsored study©λ✔↓ for the collection of bone marrow from pati¶εents with gliomas. The study will eσ$÷valuate generating marr§∞ow infiltrating lymphocytes (MILs™) f∑±€or these patients through↕₽<↑ WindMIL’s proprietary cellular activation and ♣​γ expansion process. The study is★γδ♣ being conducted at UCI.“P♠>§δatients suffering with g↕←©↑lioblastoma are in gr÷δ∏eat need of new, promising treatments that migh₽ ≥Ωt advance the current standard of care,” s∞∏‍aid Daniela A. Bota, MD, PhD, director of π the UCI Health Comprehensive Brain Tumor Pro£×₩gram, senior associate d♠​¶♠ean for clinical research, UC$ ¥βI School of Medicine and clinical dire♥εctor, UCI Sue & Bill Gross↔™ ≠ Stem Cell Research Center. “The Univ✔™ersity of California, Irvine is‍π± excited to play a k£±ey role in research tha¶>t may lead to a clinical trial that e> €nlists the immune system in©¶‍ novel ways to fightΩ↕$ this terrible disease.”Gl ε₹>iomas are the most common of the mal₽≤ε€ignant brain tumors. Glioblastoma, the moβφst common glioma, has a five-year survivalα' of less than 5 percent. Additional t  reatment options are urgently needed for these < patients. Adoptive imm$∏unotherapy is a possible appr¶δ★​oach for gliomas and the use of MILs, a cel>∏l therapy that is naturally tumor-speci∑✘Ωσfic, is one such treatment option‍‌§.The bone marrow is a unique niche in "₽♣φthe immune system to ¥✘which antigen-experience <d memory T cells traffic and are then maintained.♣☆ WindMIL has developed a proprietaα>&ry process to select, activate and ↕>≠expand these memory T cel↑♥<±ls into MILs. Because memory T cells in b©¥♣₽one marrow occur as a result of the immune↕α÷≤ system’s recognition of tumor Ωα≠≤antigens, MILs are specifically suited for ±∑β∞adoptive cellular immunotherapy and are able tπ∑o directly eradicate or facilitate eradicati  •on of each patient’s unique cancer. WindMI&&L is currently studying MILs in multip'↕γ£le myeloma, non-small cell lu&$ng cancer and squamous c≠‌™ell carcinoma of the head&§ and neck, and plans to exp÷↕→and into other solid tumo™×rs.“WindMIL is looking forwa→∑Ωrd to working with the University of Cal≥β αifornia, Irvine on this ex≈✔♣citing project and is optimistic that M€‍®<ILs may offer the po¶δ÷¶tential to help patients wit≈∑ h these hard-to-treat diseases,” said Monil S↓α←εhah, PharmD, MBA, Chief Development Officer←÷♣ at WindMIL.information φ>∏β;source:pharma focus AsiaThe original link:https:σΩ//www.pharmafocusasia.com/news€Ω/windmil-therapeutics-and-unive βrsity-of-california-irvine-↕™announce-collaboration-to-collect-bone-marrow-froγ  m-patients-with-gliom∞Ωas2019 Asia-pacific pharma IP Leade"÷ r Summit: http://en.zenseegroup.com/p/510934/wi∑∑÷ll be held in Beijing&n₹≤≤€bsp; on November 14-15, and will at↔∞tract more than 500 industry experts from ​¶ domestic and foreign pharmaceutical companies, b$£iotechnology companies, government"‍♦σs, associations, law firms, intellectual ₩•property agents and other§↔λ₽ companies to attend.Official r" ✘egistration and consultation ch≈♦¶¶annels:Contact：AnnPhone: 021-6‌ ↑®5650305Email：Marketing@zen≥ seegroup.comhttp://en.zenseegroup.απ"com/p/510934/